PBAC's latest decision on Infliximab: Recommended with restriction (2025). Considered for Multiple indications including rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults and children (6 to 17 years), refractory Crohn's disease, ankylosing spondylitis, psoriasis, and ulcerative colitis in adults and children (6 to 17 years).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
20
first 2006
PBS spend
$88M
98,550 scripts · 2024
Eligible population
Patients with rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children aged 6–17 years), refractory Crohn's disease, ankylosing spondylitis, psoriasis, and ulcerative colitis (adults and children aged 6–17 years) — same indications as other PBS-listed infliximab biosimilars.
Therapy area
Rheumatology
Line of therapy
Any
Evidence base
Other
Comparator
other brands of infliximab 100 mg powder for injection (Inflectra, Renflexis, Remicade)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as Remsima is a biosimilar with equi-effective dosing (1 mg Remsima = 1 mg Remicade) and expected to have nil financial impact through substitution.
ICER (historical)
$45k/QALY–$75k/QALY across 6 submissions (2006–2014) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
PBS expenditure
The Australian government paid $88M in PBS benefits for Infliximab in 2024 across 98,550 scripts, at $894 per script.